Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Musculoskeletal diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Study title: A multi-centre, randomised, double-blind, placebo controlled, parallel group study of oral alendronate sodium in paediatric patients with severe osteogenesis imperfecta, followed by an open label extension.
    Active substance: ALENDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46327
    Study title: An open label study to investigate the pharmacokinetic profile of alendronate in paediatric patients with osteogenesis imperfecta.
    Active substance: ALENDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46328
    Study title: 1-a-hydroxycholecalciferol treatment of long-term haemodialysis patients. Nielson, H.E. Abstract presented at the European Dialysis and Transplant Association XIIIth Congress, June 1976, Hamburg (Ref 612) 2 pts1-a-hydroxycholecalciferol treatment of long-term haemodialysis patients. Nielson, H.E. Abstract presented at the European Dialysis and Transplant Association XIIIth Congress, June 1976, Hamburg (Ref 612) 2 pts
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46330
    Study title: 1α-hydroxyvitamin D in Nutritional Rickets. Glasgow JRT, Reid M. Lancet (1977) iii, 3021α-hydroxyvitamin D in Nutritional Rickets. Glasgow JRT, Reid M. Lancet (1977) iii, 302
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46333
    Study title: A clinical study in children for One Alfa capsules (0.25 µg and 1 µg). Pr. Royer. Submitted to French authorities March 1979.A clinical study in children for One Alfa capsules (0.25 µg and 1 µg). Pr. Royer. Submitted to French authorities March 1979.
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46334
    Study title: “A clinical study in children for One Alfa capsules March 1979 Pr. Royer“A clinical study in children for One Alfa capsules March 1979 Pr. Royer
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46329
    Study title: Clinical Experiences with 1-a- hydroxy Vitamin D3 C.E. Dent and J.M. GertnerClinical Experiences with 1-a- hydroxy Vitamin D3 C.E. Dent and J.M. Gertner
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46335
    Study title: Kovar I. and Mayne P. Plasma Alkaline Phosphatase Activity in the Preterm Neonate Acta. Paediatr. Scand. (1981) 70, 501-506Kovar I. and Mayne P. Plasma Alkaline Phosphatase Activity in the Preterm Neonate Acta. Paediatr. Scand. (1981) 70, 501-506
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46336
    Study title: Long term treatment of uraemic osteodystrophy with 1-a- hydroxycholecalciferol. S. Pors Nielsen a.Proceedings of the twelfth congress of the European Dialysis and Transplant Association, Copenhagen, Denmark 1975, p221-226 b. Nephron 16: 359-370,1976 3 adolescentsLong term treatment of uraemic osteodystrophy with 1-a- hydroxycholecalciferol. S. Pors Nielsen a.Proceedings of the twelfth congress of the European Dialysis and Transplant Association, Copenhagen, Denmark 1975, p221-226 b. Nephron 16: 359-370,1976 3 adolescents
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46337
    Study title: Long term treatment of uraemic osteodystrophy with 1α-hydroxycholecalciferolLong term treatment of uraemic osteodystrophy with 1α-hydroxycholecalciferol
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46338
    Study title: Named patient data – preliminary data from Dr. A Bosley, used in 11 low birth weight infantsNamed patient data – preliminary data from Dr. A Bosley, used in 11 low birth weight infants
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46339
    Study title: Plasma Alkaline Phosphatase Activity in Rickets of Prematurity Glass E.J., Hume F., Hendry G.M.A., Strange R.C., and Forfar J.E. Submitted to Archives of Disease in ChildhoodPlasma Alkaline Phosphatase Activity in Rickets of Prematurity Glass E.J., Hume F., Hendry G.M.A., Strange R.C., and Forfar J.E. Submitted to Archives of Disease in Childhood
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46340
    Study title: Plasma Alkaline Phosphatase Activity in the Preterm Neonate Kovar I. and Mayne P. Plasma Alkaline Phosphatase Activity in the Preterm Neonate Acta. Paediatr. Scand. (1981) 70, 501-506Plasma Alkaline Phosphatase Activity in the Preterm Neonate Kovar I. and Mayne P. Plasma Alkaline Phosphatase Activity in the Preterm Neonate Acta. Paediatr. Scand. (1981) 70, 501-506
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46341
    Study title: Renal Osteodystrophy in Young children . A double blind trial of 1 alpha-hydroxycholecalciferol' Dr S Rigden Jones & Barratt. London.Renal Osteodystrophy in Young children . A double blind trial of 1 alpha-hydroxycholecalciferol' Dr S Rigden Jones & Barratt. London.
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46342
    Study title: Summary of reports on named patients treated with One Alpha drops Dr C ChantierSummary of reports on named patients treated with One Alpha drops Dr C Chantier
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46344
    Study title: Treatment of renal bone disease with 1a-hydroxycholecalciferol in the treatment of renal osteodystrophy. Kanis, J.A, Summary Report, August 1976, BMJ,10.7.1976, pp79-83Treatment of renal bone disease with 1a-hydroxycholecalciferol in the treatment of renal osteodystrophy. Kanis, J.A, Summary Report, August 1976, BMJ,10.7.1976, pp79-83
    Active substance: ALFACALCIDOL
    Study summary document link (including results):
    View full study record
    Document reference: 46343
    Study title: Therapieerfahrungen mit Arnika und Hydroxyethylsalicylat in einem Akut-Spray
    Active substance: ARNICA AND SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 21831
    Study title: Castells S, et all. Therapy of osteogenesis imperfecta with synthetic salmon calcitonin. J Pediatr. 1979 Nov;95(5 Pt 1):807-11.Castells S, et all. Therapy of osteogenesis imperfecta with synthetic salmon calcitonin. J Pediatr. 1979 Nov;95(5 Pt 1):807-11.
    Active substance: CALCITONIN (SALMON)
    Study summary document link (including results):
    View full study record
    Document reference: 23145
    Study title: Effect of Calcitonin Administration on Young Pig Trabecular Bone Remodeling - M. C. De Vernejoul et al. - 1990 (Bone 1990; 11: 29-33)Effect of Calcitonin Administration on Young Pig Trabecular Bone Remodeling - M. C. De Vernejoul et al. - 1990 (Bone 1990; 11: 29-33)
    Active substance: CALCITONIN (SALMON)
    Study summary document link (including results):
    View full study record
    Document reference: 23144
    Study title: Nishi Y, et all. Vitamin D metabolism in osteogenesis imperfecta during calcitonin therapy. Pediatrics. 1984 Apr;73(4):538-42.Nishi Y, et all. Vitamin D metabolism in osteogenesis imperfecta during calcitonin therapy. Pediatrics. 1984 Apr;73(4):538-42.
    Active substance: CALCITONIN (SALMON)
    Study summary document link (including results):
    View full study record
    Document reference: 23143
    1  2  3  4  5  6  7  8  9  Next» Last»»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 21:04:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA